Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 473 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Paranasal Sinus Diseases Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents

NCT00948519
View directory record Official record
Conditions
Rhinosinusitis
Interventions
Laser + ICG, Laser only
Device
Lead sponsor
New York Head & Neck Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Not applicable Interventional

SAVEPACe - Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction

NCT00284830
View directory record Official record
Conditions
Sick Sinus Syndrome, Heart Failure, Congestive, Atrial Fibrillation, Bradycardia, Ventricular Dysfunction
Interventions
Implantable Pulse Generators
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
1,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
63
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Conway, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2008 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Acupuncture and Herbal Treatment of Chronic HIV Sinusitis

NCT00002149
View directory record Official record
Conditions
HIV Infections, Sinusitis
Interventions
Clavulanate potassium, Pseudoephedrine hydrochloride, Amoxicillin trihydrate
Drug
Lead sponsor
Immune Enhancement Project
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

NCT02296190
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions
Etripamil, Placebo
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Phoenix, Arizona • Sacramento, California • Littleton, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 2 Interventional

Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck

NCT00033618
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
ixabepilone, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

NCT00397384
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer

NCT01254617
View directory record Official record
Conditions
Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Rectal Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Verrucous Carcinoma AJCC v7, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Verrucous Carcinoma AJCC v7, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Rectal Cancer AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Verrucous Carcinoma AJCC v7, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Tongue Carcinoma
Interventions
Cetuximab, Laboratory Biomarker Analysis, Lenalidomide
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 2 Interventional

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

NCT02145884
View directory record Official record
Conditions
Hemangioma
Interventions
timolol maleate 0.5% gel
Drug
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
7 Days to 6 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 10, 2026, 8:15 PM EDT
Terminated Not applicable Interventional Results available

Left Bundle Area Versus Selective His Bundle Pacing

NCT04093414
View directory record Official record
Conditions
Bradycardia, Sinus Node Dysfunction, Atrioventricular Block
Interventions
Select Secure pacing lead
Device
Lead sponsor
David Haines, MD
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 10, 2026, 8:15 PM EDT
Completed No phase listed Observational Results available

Home Usability of a Nasal Lavage System in Children

NCT01129765
View directory record Official record
Conditions
Nasal Congestion, Respiratory Tract Infection, Sinusitis, Allergic Rhinitis
Interventions
Use of an automatic nasal irrigator/aspirator
Device
Lead sponsor
Aardvark Medical Company
Industry
Eligibility
Up to 5 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 10, 2026, 8:15 PM EDT
Recruiting Phase 2 Interventional

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

NCT07063212
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Sacituzumab Govitecan, Cetuximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 10, 2026, 8:15 PM EDT
Completed No phase listed Observational

Imaging Cardiac Electrical Remodeling With Electrocardiogram Imaging (ECGI)

NCT00785564
View directory record Official record
Conditions
Sick Sinus Syndrome
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Not applicable Interventional

The Fluoroless-CSP Trial Using Electroanatomic Mapping

NCT03903107
View directory record Official record
Conditions
Sinus Node Dysfunction, Heart Block AV, LBBB, Heart Failure, Systolic
Interventions
Conventional fluoroscopy guided Conduction System Pacing(CSP), Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 10, 2026, 8:15 PM EDT
Terminated No phase listed Observational

Risk Factors That Contribute to the Maintenance of Sinus Rhythm

NCT04655443
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Standard Care
Other
Lead sponsor
Danbury Hospital
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 10, 2026, 8:15 PM EDT
Recruiting Not applicable Interventional

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

NCT06662058
View directory record Official record
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions
Audiometric Test, Interview
Procedure · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 4 Interventional

Study of Nasal Irrigation Versus Nasal Spray for Chronic Nasal and Sinus Symptoms

NCT00318006
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
saline irrigation, saline spray
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Oct 10, 2026, 8:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Near Infrared Transillumination of the Paranasal Sinuses

NCT00543998
View directory record Official record
Conditions
Sinusitis
Interventions
Optical Measurement transillumination
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
15 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
2
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 10, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional

Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation

NCT05039359
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
FlecIH-103
Drug
Lead sponsor
InCarda Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
18
States / cities
Davis, California • Long Beach, California • Bridgeport, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

NCT00023959
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
hydroxyurea, fluorouracil, bevacizumab, radiation therapy, filgrastim, laboratory biomarker analysis
Drug · Biological · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 10, 2026, 8:15 PM EDT
Withdrawn Phase 1 Interventional

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

NCT01332279
View directory record Official record
Conditions
Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
Interventions
everolimus, erlotinib hydrochloride, biopsy, laboratory biomarker analysis, immunohistochemistry staining method, polyacrylamide gel electrophoresis, pharmacological study, external beam radiation therapy, microarray analysis
Drug · Procedure · Other + 2 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

Xylitol Versus Saline in Chronic Sinusitis

NCT00924404
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
Xylitol, Saline
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide

NCT00791934
View directory record Official record
Conditions
Sinusitis
Interventions
Stratus Microflow Ethmoid Spacer
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
17 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SinuSurf vs. Saline Solution in Normal Subjects

NCT02728505
View directory record Official record
Conditions
Rhinosinusitis
Interventions
SinuSurf irrigation twice daily, NeilMed Sinus rinse irrigation twice daily
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 10, 2026, 8:15 PM EDT
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 10, 2026, 8:15 PM EDT